Ethyl-substituted erythromycin derivatives produced by directed metabolic engineering.

Proc Natl Acad Sci U S A

Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064, USA.

Published: June 1998

A previously unknown chemical structure, 6-desmethyl-6-ethylerythromycin A (6-ethylErA), was produced through directed genetic manipulation of the erythromycin (Er)-producing organism Saccharopolyspora erythraea. In an attempt to replace the methyl side chain at the C-6 position of the Er polyketide backbone with an ethyl moiety, the methylmalonate-specific acyltransferase (AT) domain of the Er polyketide synthase was replaced with an ethylmalonate-specific AT domain from the polyketide synthase involved in the synthesis of the 16-member macrolide niddamycin. The genetically altered strain was found to produce ErA, however, and not the ethyl-substituted derivative. When the strain was provided with precursors of ethylmalonate, a small quantity of a macrolide with the mass of 6-ethylErA was produced in addition to ErA. Because substrate for the heterologous AT seemed to be limiting, crotonyl-CoA reductase, a primary metabolic enzyme involved in butyryl-CoA production in streptomycetes, was expressed in the strain. The primary macrolide produced by the reengineered strain was 6-ethylErA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC22598PMC
http://dx.doi.org/10.1073/pnas.95.13.7305DOI Listing

Publication Analysis

Top Keywords

produced directed
8
6-ethylera produced
8
domain polyketide
8
polyketide synthase
8
ethyl-substituted erythromycin
4
erythromycin derivatives
4
produced
4
derivatives produced
4
directed metabolic
4
metabolic engineering
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!